SOUTH SAN FRANCISCO, CA--(Marketwire - April 30, 2009) - Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the Bank of America and Merrill Lynch 2009 Health Care Conference on Wednesday, May 13, 2009, at 10:00 a.m. EDT. The conference will be held from March 12-14, 2009 at The Palace Hotel in New York City.
The presentation will be webcast live and can be reached from Theravance's web site at www.theravance.com. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.
About Theravance
Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. The company's key programs include: telavancin for the treatment of serious Gram-positive bacterial infections with Astellas Pharma Inc. and the Horizon program and Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program with GlaxoSmithKline plc. By leveraging its proprietary insight of multivalency toward drug discovery focused primarily on validated targets, Theravance is pursuing a next generation strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit the company's web site at www.theravance.com.
THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.
Theravance's presentation at the Bank of America and Merrill Lynch 2009
Health Care Conference will contain certain "forward-looking" statements as
that term is defined in the Private Securities Litigation Reform Act of
1995 regarding, among other things, statements relating to goals, plans,
objectives and future events. Theravance intends such forward-looking
statements to be covered by the safe harbor provisions for forward-looking
statements contained in Section 21E of the Exchange Act and the Private
Securities Litigation Reform Act of 1995. Examples of such statements
include statements relating to the goals and timing of clinical studies,
statements regarding the potential benefits and mechanisms of action of
drug candidates, statements concerning the timing of seeking regulatory
approval of our product candidates (including with respect to telavancin
statements regarding any expectation that the third-party manufacturer will
successfully address the cGMP issues the FDA noted in the approvable letter
or that regulatory authorities will approve telavancin on the basis of
existing preclinical and clinical data or at all), statements concerning
enabling capabilities of Theravance's approach to drug discovery and its
proprietary insights, and statements regarding expectations for product
candidates through development and commercialization and projections of
revenue and other financial items. These statements are based on the
current estimates and assumptions of the management of Theravance as of the
date of the presentation and are subject to risks, uncertainties, changes
in circumstances, assumptions and other factors that may cause the actual
results of Theravance to be materially different from those reflected in
its forward-looking statements. Important factors that could cause actual
results to differ materially from those indicated by such forward-looking
statements include, among others, risks related to delays or difficulties
in commencing or completing clinical studies, risks related to the
potential that results of clinical or preclinical studies indicate product
candidates are unsafe or ineffective, our dependence on third parties in
the conduct of our clinical studies, delays or failure to achieve
regulatory approvals for, or to successfully launch, product candidates,
risks of relying on third-party manufacturers for the supply of our product
candidates and risks of collaborating with third parties to develop and
commercialize products. These and other risks are described in greater
detail under the heading "Risk Factors" contained in Theravance's Annual
Report on Form 10-K filed with the Securities and Exchange Commission (SEC)
on February 26, 2009 and the risks discussed in our other periodic filings
with the SEC. Given these uncertainties, you should not place undue
reliance on these forward-looking statements. Theravance assumes no
obligation to update its forward-looking statements.
